BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indicated for the treatment of metastatic colorectal cancer patients, but some scientific issues concerning their efficacy are currently unsolved. METHODS: A literature-based meta-analysis was conducted. Hazard ratios (HRs) were extracted from randomized trials for progression-free survival (PFS) and overall survival (OS); the event-based risk ratio was derived for response. Sensitivity analyses to look for interactions according to KRAS status and chemotherapy association regimens were performed. RESULTS: Eight trials (6609 patients) were identified. A significant interaction according to KRAS status was found for PFS (wild type vs mutant, P ...
Background: Metastatic colorectal cancer (mCRC) tumours harbouring a RAS mutation are associated wit...
Clinical studies showed that only 10% of patients with metastatic colorectal cancer (mCRC) respond t...
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial grow...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...
This meta-analysis was performed to determine the optimal use of anti-EGFR mAb in the treatment of m...
Monoclonal antibodies directed against the EGF-receptor (EGFR) have recently been approved for the t...
Background: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients...
BACKGROUND: Two groups of agents targeting either the vascular endothelial growth factor (VEGF) rece...
Background: The use of anti-EGFR monoclonal antibodies (MoAbs) is restricted in Europe to RAS wild-t...
Background: In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are not curre...
Background: In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are not curre...
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial imp...
Background: Emerging data suggest that somatic KRAS mutation in advanced colorectal cancer is a stro...
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial grow...
Background: Metastatic colorectal cancer (mCRC) tumours harbouring a RAS mutation are associated wit...
Clinical studies showed that only 10% of patients with metastatic colorectal cancer (mCRC) respond t...
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial grow...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...
BACKGROUND: Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indic...
This meta-analysis was performed to determine the optimal use of anti-EGFR mAb in the treatment of m...
Monoclonal antibodies directed against the EGF-receptor (EGFR) have recently been approved for the t...
Background: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients...
BACKGROUND: Two groups of agents targeting either the vascular endothelial growth factor (VEGF) rece...
Background: The use of anti-EGFR monoclonal antibodies (MoAbs) is restricted in Europe to RAS wild-t...
Background: In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are not curre...
Background: In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are not curre...
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial imp...
Background: Emerging data suggest that somatic KRAS mutation in advanced colorectal cancer is a stro...
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial grow...
Background: Metastatic colorectal cancer (mCRC) tumours harbouring a RAS mutation are associated wit...
Clinical studies showed that only 10% of patients with metastatic colorectal cancer (mCRC) respond t...
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial grow...